Phase 3Completed
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus
- Sponsor
- Eli Lilly and Company (Industry)
- Enrollment
- 394 enrolled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- LY2189265; Sulfonylureas (SU); Biguanides (BG); alpha-glucosidase inhibitor (a-GI); Thiazolidinedione (TZD); Glinides
- Ages
- adults, older adults
- Registry
- NCT01468181
Full record on ClinicalTrials.gov
From the registry
This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication (OAM).
Primary outcomes
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
- Percentage of Participants With Hypoglycemic Episodes
History
Last registry update
Results first posted
Primary completion
Started
Registered